Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies

Mayo Clinic Proceedings

Volumn 89, Issue 2, 2014, Pages 225-240

  Wingerchuk, Dean M ^a   Carter, Jonathan L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; COLESTYRAMINE; DACLIZUMAB; FINGOLIMOD; FUMADERM; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; OCRELIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; DMF; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ACUTE LEUKEMIA; ADD ON THERAPY; AGE DISTRIBUTION; ALOPECIA; AUTOIMMUNE THYROIDITIS; BRADYCARDIA; CARDIOMYOPATHY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC DISEASE; COCHRANE LIBRARY; DEMYELINATING DISEASE; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; EARLY DIAGNOSIS; EMBASE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GOODPASTURE SYNDROME; GRAVES DISEASE; GRAY MATTER; HEART PALPITATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; INFORMATION RETRIEVAL; INFUSION RELATED REACTION; INJECTION SITE REACTION; LEUKOPENIA; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MEDLINE; MONOTHERAPY; MULTIPLE SCLEROSIS; NAUSEA; NERVE DEGENERATION; NERVOUS SYSTEM FUNCTION; NEUROIMAGING; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHARYNGITIS; PREDICTION; PREGNANCY; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RELAPSE; RETINA MACULA EDEMA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SELF INJECTION; SEX DIFFERENCE; SKIN MANIFESTATION; THYROID PAPILLARY CARCINOMA; TREATMENT PLANNING; VIRUS INFECTION; WHITE MATTER; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DISEASE-MODIFYING THERAPY; DMT; EDSS; EXPANDED DISABILITY STATUS SCALE; FOOD AND DRUG ADMINISTRATION; GA; JC VIRUS; JCV; NUCLEAR MAGNETIC RESONANCE IMAGING; PML; PPMS; RRMS; S1P; SPHINGOSINE-1-PHOSPHATE; SPMS;

BBB; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CNS; DIMETHYL FUMARATE; DISEASE-MODIFYING THERAPY; DMF; DMT; EDSS; EXPANDED DISABILITY STATUS SCALE; FDA; FOOD AND DRUG ADMINISTRATION; GA; GLATIRAMER ACETATE; JCV; JOHN CUNNINGHAM VIRUS; MAGNETIC RESONANCE IMAGING; MRI; MS; MULTIPLE SCLEROSIS; PML; PPMS; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELAPSING-REMITTING MULTIPLE SCLEROSIS; RRMS; S1P; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; SPHINGOSINE-1-PHOSPHATE; SPMS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 84897574115     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.11.002     Document Type: Review

References (134)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
2. International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214-219.
3. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol. 2010;6(3):156-166.
4. Orton SM, Herrera BM, Yee IM, et al; Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5(11):932-936.
5. Wu N, Minden SL, Hoaglin DC, Hadden L, Frankel D. Quality of life in people with multiple sclerosis: data from the Sonya Slifka Longitudinal Multiple Sclerosis Study. J Health Hum Serv Adm. 2007;30(3):233-267.
6. Marrie RA, Horwitz RI. Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol. 2010;9(8):820-828.
7. Feinstein A. Multiple sclerosis and depression. Mult Scler. 2011;17(11):1276-1281.
8. Trisolini M, Honeycutt A, Wiener J, Lesesne S. Global economic impact of multiple sclerosis. 2010. Multiple Sclerosis International Federation website. http://www.msif.org/includes/documents/cm-docs/2011/g/global-economic-impact-of- ms.pdf?f=1. Accessed August 29, 2013.
9. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639-647.
10. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012;7:185-217.
11. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008;7(9):841-851.
12. Lucchinetti CF, Popescu BF, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365(23):2188-2197.
13. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005;26(9):485-495.
14. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502- 1517.
15. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol. 2006;27(2):455-461.
16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911.
17. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
18. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11(2):157-169.
19. Miller DH, Leary SM. Primary-progressive multiple sclerosis [published correction appears in Lancet Neurol. 2009;8(8):699]. Lancet Neurol. 2007;6(10):903-912.
20. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528-1532.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452.
22. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, I: clinical course and disability. Brain. 1989;112(Pt 1):133-146.
23. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006;5(4):343-354.
24. Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. 2004;56(2):303-306.
25. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(8, Suppl 4):S3-S9.
26. Jacobs LD, Beck RW, Simon JH, et al; CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
27. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-1249.
28. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397.
29. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial [published correction appears in Lancet. 2010;375(9724):1436]. Lancet. 2009;374(9700):1503-1511.
30. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285.
31. Jacobs LD, Cookfair DL, Rudick RA, et al. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [published correction appears in Ann Neurol. 1996;40(3):480]. Ann Neurol. 1996;39(3):285-294.
32. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [published correction appears in Lancet. 1999;353(9153):678]. Lancet. 1998;352(9139):1498-1504.
33. The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology. 1999;53(4):679-686.
34. Johnson KP, Brooks BR, Cohen JA, et al. The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 1995;45(7):1268-1276.
35. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002;59(10):1496-1506.
36. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352(9139):1491-1497.
37. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63(10):1779-1787.
38. Panitch H, Miller A, Paty D, Weinshenker B. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788-1795.
39. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MSSG. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56(11):1496-1504.
40. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9(7):740-750.
41. Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler. 2012;18(5):610-615.
42. Wingerchuk DM. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management. Expert Rev Neurother. 2006;6(3):333-346.
43. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler. 2012;18(7):932-946.
44. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, GALA Study Group. Three times weekly glatiramer acetate in relapsingremitting multiple sclerosis. Ann Neurol. 2013;73(6):705-713.
45. Calabresi P, Kieserer B, Arnold D, et al. Clinical efficacy and safety of peginterferon beta-1a in relapsing multiple sclerosis: data from the Pivotal Phase 3 ADVANCE Study. Neurology. 2013;80(Meeting Abstracts 1):S31.006.
46. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-2025.
47. Marriott JJ, Miyasaki JM, Gronseth G, et al. Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463-1470.
48. Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007;356(25):2622-2629.
49. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
50. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
51. Freedman MS. Present and emerging therapies for multiple sclerosis. Continuum (Minneap Minn). 2013;19(4 Multiple Sclerosis):968-991.
52. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381.
53. Kleinschmidt-De Masters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353(4):369-374.
54. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35-47.
55. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
56. Global natalizumab (TYSABRI) safety update. Weston, MA: Biogen Idec; October 1, 2013.
57. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumabtreated MS patients. Neurology. 2013;81(10):865-871.
58. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.
59. Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84-90.
60. Major EO, Frohman E, Douek D. JC viremia in natalizumabtreated patients with multiple sclerosis. N Engl J Med. 2013;368(23):2240-2241.
61. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430-1438.
62. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402-409.
63. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77(11):1061-1067.
64. Calabresi PA, Giovannoni G, Confavreux C, et al; AFFIRM and SENTINEL Investigators. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391-1403.
65. Rigau V, Mania A, Béfort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology. 2012;79(22):2214-2216.
66. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858-1865.
67. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? Ann Neurol. 2010;68(3):395-399.
68. Borriello G, Prosperini L, Mancinelli C, Giannì C, Fubelli F, Pozzilli C. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol. 2012;19(5):783-787.
69. Sempere AP, Martín-Medina P, Berenguer-Ruiz L, et al. Switching from natalizumab to fingolimod: an observational study. Acta Neurol Scand. 2013;128(2):e6-e10.
70. Cohen M, Maillart E, Papeix C, et al. ENIGM: a French observational study about switching from natalizumab to fingolimod in multiple sclerosis. Neurology. 2013;80(Meeting Abstracts 1):S41.002.
71. Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2013;20(1):87-94.
72. Kappos L, Radue EW, O'Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
73. Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
74. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759-777.
75. Noda H, Takeuchi H, Mizuno T, Suzumura A. Fingolimod phosphate promotes the neuroprotective effects of microglia. J Neuroimmunol. 2013;256(1-2):13-18.
76. Ratchford JN, Costello K, Reich DS, Calabresi PA. Varicellazoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology. 2012;79(19):2002-2004.
77. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
78. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78(9):672-680.
79. FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). Food and Drug Adminstration website. http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm. Accessed September 6, 2013.
80. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol. 2012;142(1):49-56.
81. O'Connor P, Wolinsky JS, Confavreux C, et al; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
82. Miller A, Kappos L, Comi G, et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from TOWER, a second, pivotal, phase 3 placebo-controlled study. Neurology. 2013;80(Meeting Abstracts 1):S01.004.
83. Oh J, O'Connor PW. Teriflunomide. Neurol Clin Pract. 2013;3(3):254-260.
84. Aubagio [package insert]. Cambridge, MA: Genzyme Corporation; 2013.
85. Alcorn N, Saunders S, Madhok R Benefit-risk assessment of leflunomide: an appraisl of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf. 2009;32:1123-1134.
86. Wiese MD, Rowland A, Polasek TM, Sorich MJ, O'Doherty C. Pharmacokinetic evaluation of teriflunomide forthe treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol. 2013;9(8):1025-1035.
87. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134(Pt 3):678-692.
88. Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163.
89. Ropper AH. The "poison chair" treatment for multiple sclerosis. N Engl J Med. 2012;367(12):1149-1150.
90. Fox RJ, Miller DH, Phillips JT, et al; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis [published correction appears in N Engl J Med. 2012;367(17):1673]. N Engl J Med. 2012;367(12):1087-1097.
91. Gold R, Kappos L, Arnold DL, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107.
92. Tecfidera [package insert]. Cambridge, MA: Biogen Idec; 2013.
93. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657-1658.
94. Van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy [published correction appears in N Engl J Med. 2013;368(20):1950]. N Engl J Med. 2013;368(17):1658-1659.
95. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368(17):1659-1661.
96. Cohen JA, Coles AJ, Arnold DL, et al; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819-1828.
97. Coles AJ, Twyman CL, Arnold DL, et al; CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.
98. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-579.
99. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052-2061.
100. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol. 2012;19(2):307-311.
101. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688.
102. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67(4):452-461.
103. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsingremitting multiple sclerosis: a phase 2, randomised, placebocontrolled, multicentre trial. Lancet. 2011;378(9805):1779-1787.
104. Noseworthy JH, Wolinsky JS, Lublin FD, et al; North American Linomide Investigators. Linomide in relapsing and secondary progressive MS, Part I: trial design and clinical results. Neurology. 2000;54(9):1726-1733.
105. Comi G, Jeffery D, Kappos L, et al; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-1009.
106. Vollmer TL, Soelberg Sorensen P, Arnold DL, on behalf of the BRAVO Study Group. A placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. MSJ. 2011;17:S507-S508.
107. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta [published correction appears in Proc Natl Acad Sci U S A. 2004;101(50):17565]. Proc Natl Acad Sci U S A. 2004;101(23):8705-8708.
108. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007;69(8):785-789.
109. Wynn D, Kaufman M, Montalban X, et al; CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta [published correction appears in Lancet Neurol. 2010;9(8):759. Wadinger, K [corrected to Wandinger, K]]. Lancet Neurol. 2010;9(4):381-390.
110. Sheridan JP, Zhang Y, Riester K, et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56 (bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler. 2011;17(12):1441-1448.
111. Gold R, Giovannoni G, Selmaj K, et al; SELECT Study Investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167-2175.
112. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology. 2012;78(17):1315-1322.
113. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308(3):247-256.
114. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. Eur Neurol. 2009;61(3):177-182.
115. Healy BC, Glanz BI, Stankiewicz J, Buckle G, Weiner H, Chitnis T. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010;16(12):1483-1489.
116. Sormani MP, De Stefano N. Defining and scoring response to IFN-beta in multiple sclerosis. Nat Rev Neurol. 2013;9(9):504-512.
117. Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12(7):669-676.
118. Goodin DS, Traboulsee A, Knappertz V, et al; 16-Year Long Term Follow-up Study Investigators. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):282-287.
119. Hutchinson M, Kappos L, Calabresi PA, et al; AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL [published correction appears in J Neurol.2009;256(6):1035-1037]. J Neurol. 2009;256(3):405-415.
120. Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: why? when? how? CNS Drugs. 2013;27(6):403-409.
121. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009;277(Suppl 1):S42-S45.
122. Edan G, Comi G, Le Page E, et al. FrencheItalian Mitoxantrone Interferon-beta-1b Trial Group. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82(12):1344-1350.
123. Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14(5):663-670.
124. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430-1438.
125. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296-304.
126. Lublin FD, Cofield SS, Cutter GR, et al; CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013;73(3):327-340.
127. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390-1395.
128. Sorensen PS, Lycke J, Eralinna JP, et al; SIMCOMBIN Study Investigators. Simvastatin as add-on therapy to interferon b-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011;10(8):691-701.
129. Kieseier BC, Stüve O. Multiple sclerosis: combination therapy in MSdstill a valid strategy. Nat Rev Neurol. 2011;7(12):659-660.
130. Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009;132(Pt 12):3353-3365.
131. Rudick RA, Rani MR, Xu Y, et al. Excessive biologic response to IFNbeta is associated with poor treatment response in patients with multiple sclerosis. PLoS One. 2011;6(5):e19262.
132. Axtell RC, De Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010;16(4):406-412.
133. Bushnell SE, Zhao Z, Stebbins CC, et al. Serum IL-17F does not predict poor response to IM IFNbeta-1a in relapsingremitting MS. Neurology. 2012;79(6):531-537.
134. Derfuss T. Personalized medicine in multiple sclerosis: hope or reality? BMC Med. 2012;10:116.